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Abstract 
Irritable bowel syndrome (IBS) is considered to be a physical disorder that mainly 
affects the bowel and is clinically characterized by lower abdominal pain or discomfort, 
diarrhea, constipation (or alternating diarrhea/constipation), gas, bloating, and nausea. 
According to recent studies, it appears that there is an association with increased 
prolactin levels in patients suffering from IBS. We report a rare case of regression of IBS 
symptoms (constipation type) in a 16-year-old female adolescent after receiving 
cabergoline for treating hyperprolactinemia due to pituitary macroadenoma. Our 
hypothesis is that increased prolactin levels, for instance due to a pituitary adenoma, 
may suppress prolactin-releasing peptide release and lead to a reverse feedback 
interaction, consequently resulting in oversecretion of cholecystokinin, inducing the 
development of IBS. 
 
Introduction 
Irritable bowel syndrome (IBS) is the most common of all gastrointestinal disorders, 
affecting around 15% of the population at least in Western societies. The division of 
IBS into subgroups is based on the fact that these patients behave in dissimilar ways. 
IBS subgroups building on stool and defecation patterns can be divided into diarrhea-
predominant (D-IBS), constipation-predominant (C-IBS) and alternating (A-IBS) 
subtypes [1]. From recent studies, it appears that cholecystokinin (CCK) levels are 
statistically significantly higher in patients with IBS [2]. CCK belongs to the group of Case Rep Gastroenterol 2011;5:523–527 
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endogenous molecules known as ‘brain-gut neuropeptides’. CCK is found in the nerves 
of the circular muscle layer of the colon and to some extent in the ileum, and it is 
abundant in the celiac plexus and vagus nerves [3]. Due to these multiple anatomical 
locations it is not surprising that CCK has been implicated in different physiological 
functions: gallbladder contraction and pancreatic enzyme secretion, as well as motor 
and sensory functions at various levels of the gastrointestinal tract such as gastric 
emptying and colonic motility [4]. Further studies have shown that CCK also acts as a 
mediator of the gastrocolonic response [5, 6], while CCK infusion appears to unmask 
intestinal dysmotility in patients with IBS [7]. Except for this, new studies suggest that 
there is a strong correlation between CCK and the prolactin-releasing peptide (PrRP), 
since peripheral administration of CCK is proven to activate neurons expressing PrRP 
[8]. As a result, increased prolactin levels, for instance due to a pituitary adenoma, may 
suppress the secretion of PrRP and lead to a reverse feedback, consequently resulting 
in oversecretion of CCK, inducing the development of IBS. Nevertheless, to the best 
of our knowledge, there are no studies regarding the CCK levels in pathological 
hyperprolactinemia that estimate the possible benefit of regression of IBS after receiving 
dopaminergic agonists for treating hyperprolactinemia. We report a unique case of 
confronting C-IBS symptoms in a female adolescent who was under cabergoline as a 
treatment of pituitary macroprolactinoma. 
Case Report 
A 16-year-old female addressed the Emergency Department complaining of acute abdominal pain 
of the periumbilical area without reporting any other symptoms. History examination revealed the 
presence of similar episodes in the past few months, most of the times relieved with defecation, which 
remained undiagnosed despite full-scale examinations, including colonoscopy and abdominal CT. The 
patient also mentioned that, since the last year, she suffered of constipation, reporting 1–2 movements 
per week. In addition, she reported catamenial disorders (complete disarrangement of the catamenial 
circle) since the previous year, without dysmenorrhea. The following complete physical examination 
and laboratory tests did not reveal the existence of an underlying cause concerning the abdominal pain. 
Abdominal X-ray revealed mediocre dilatation of the intestinal loops, without other pathological 
findings. The patient underwent abdominal and gynecological ultrasound examination without any 
pathological findings. In the meantime the pain spontaneously regressed completely. Due to the 
complete lack of pathological signs, and taking into consideration the reported catamenial disorders, a 
full endocrinological test set was performed, revealing prolactin levels of 456.04 ng/ml. In consequence, 
a pituitary gland MRI was performed, revealing a pituitary macroadenoma (1.2 × 1 × 1 cm), confirming 
the endocrinological results (fig. 1). The patient then was submitted to treatment with cabergoline. 
Prolactin levels returned to normal after almost 3 years since the beginning of the treatment, a fact that 
was mainly attributed to the patient’s reluctancy to follow the treatment plan closely. The initial 
cabergoline dose was set at 1 mg/week and was gradually elevated to 4 mg/week. The response to the 
dose was evaluated by regular measurement of prolactin levels every 6 months. During the period the 
patient was receiving cabergoline, she noticed a dramatic decrease of the cramping abdominal pain 
episodes, from 10–12 before the administration of cabergoline to only 3 after the submission to the 
particular treatment. Moreover, she mentioned that her bowel habits had been absolutely normalized, 
with almost daily defecation. The length of this period seems to be reasonable to suggest regression of 
the IBS symptoms, which can be attributed to cabergoline, through the pathophysiological pathways 
presented. 
Discussion 
Prolactin has many effects, including regulating lactation through stimulation of 
the mammary glands to produce milk (lactation), and provides the body with sexual Case Rep Gastroenterol 2011;5:523–527 
DOI: 10.1159/000331806 
Published online: 
September 3, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–0631 
www.karger.com/crg   
 
 
 
525
gratification after sexual acts. Prolactin also stimulates the proliferation of 
oligodendrocyte precursor cells. It also has a number of other effects, including 
contributing to surfactant synthesis of the fetal lungs at the end of pregnancy and to 
immune tolerance of the fetus by the maternal organism during pregnancy; it also 
decreases the normal levels of sex hormones – estrogen in women and testosterone in 
men. In addition, it appears that prolactin has a crucial role as an immunoregulator 
affecting the development of the neonatal intraepithelial T lymphocytes found between 
the epithelial cells of the small intestine [9]. Furthermore, the expression of prolactin 
transcripts has also been clearly observed in intraepithelial lymphocytes purified from 
mouse intestine [10]. From this point of view, it can be explained that prolactin levels 
significantly increase in active celiac disease [11] as well as in colorectal cancer [12], with 
research suggesting that prolactin may be a reliable biomarker regarding the activity and 
severity of these two conditions. We must take into account that there are indications 
giving reason to believe patients with IBS have ‘low-grade intestinal inflammation’, and 
the increase in T lymphocytes and mast cells has been associated with disorders found 
in IBS, such as the communication between the intestine and the nervous system, the 
increase in intestinal permeability and changes in the microbiota [13]. Therefore, it can 
be suggested that prolactin levels can reasonably rise in these patients. 
Regarding the correlation of CCK and PrRP, CCK is released from the gut in response 
to meals and has an important regulatory role in gastrointestinal function, inhibiting 
gastric motility and emptying via a neural reflex within the caudal brainstem or via a 
reflex loop that ascends to the hypothalamus via a relay in the caudal brainstem [14, 15]. 
Peripheral CCK acts on afferent nerve fibers of the gastric vagus nerve; these vagal 
neurons project to the caudal brainstem [16], where they activate neurons that project to 
hypothalamic nuclei involved in appetite regulation [14, 15]. In particular, peripheral 
injections of CCK activate neurons in the nucleus tractus solitarii and ventrolateral 
medulla, including specific subpopulations of the noradrenergic neurons of the A1 and 
A2 cell groups [17]. These noradrenergic neurons comprise several subpopulations, 
which are anatomically, biochemically and functionally separate. Some of these 
noradrenergic neurons express PrRP [18]. For this reason, prolactin can be directly 
associated to the regulation of gastrointestinal mobility. Our hypothesis is that increased 
prolactin levels, for instance due to a pituitary adenoma, may suppress PrRP release and 
lead to a reverse feedback interaction, consequently resulting in oversecretion of CCK, 
inducing the development of IBS. In order to reach safe conclusions, further studies are 
needed to directly describe the interaction between hyperprolactinemia and CCK, 
especially after administrating dopaminergic agonists, so as to technically decrease 
prolactin levels, and estimate the possibility of their use as a treatment option in IBS. 
Conclusions 
Increased prolactin levels are proven to be significantly higher in patients suffering 
from C-IBS. An interesting case of regression of IBS symptoms in a patient with 
prolactinoma, after receiving cabergoline for treating hyperprolactinemia, is presented. 
The close relation of prolactin and CCK seems to have a crucial role regarding the 
regulation of intestinal mobility and could possibly indicate future therapeutic 
perspectives. Case Rep Gastroenterol 2011;5:523–527 
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Fig. 1. MRI image of the pituitary adenoma: the adenoma measured 1.2 × 1 × 1 cm, therefore it was 
classified as a macroadenoma. There were no signs of suppression of the optic chiasm, in accordance to 
the lack of relative neurological symptoms. 
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